J. Am. Med. Assoc. 321, 2463 -2464 2019) found that fewer than half of these places employ physicians who are trained in all of the conditions that they purport to treat. There are multiple reports of unapproved, unregulated therapies leaving some people blind and others with harmful tumours on their spines.
CIRM has regularly denounced these clinics, which existed before the institute's creation and will persist as long as they can make money. Still, it is easy to understand how public enthusiasm would spill over to those offering quackery.
My colleagues and I are horrified that we might be lumped with these bad actors. They exploit people and put them at risk. They confuse people by pretending to be in the scientific community and are why the term 'stem cell' has become synonymous with 'snake oil' .
This conflation is, in my view, one reason that, just as stem-cell researchers have advanced projects to the point of launching expensive clinical trials, financial support is ebbing away.
CIRM's founders have announced plans to approach voters in 2020 for another influx of funds. The likelihood of stem-cell treatments being approved is much closer to reality than it was 15 years ago, in large part because of the agency's support. But any future advertising must emphasize the necessity of rigorous scientific evidence alongside the potential of the cells.
We must strike a balance between future potential and current reality when we talk to the public. Researchers should emphasize that even when therapies show promise in mice, they often fail to work in humans. The only way to find out -and to check for safety -is rigorous scientific testing in clinical trials. I often talk to community groups about stem cells, but I think the best way I convey the message is talking with Uber drivers on my way to airports. If they understand what stem cells are and what it takes to develop therapies that will be safe and effective, maybe future passengers will learn the story and pass it on.
I am heartened that the Medical Board of California will take up the topic of unregulated 'stem-cell treatments' this month. The FDA is gaining momentum in its efforts to close places offering bogus therapies, several of which are also being sued for harming patients. I have confidence that, when the FDA approves stem-cell-based therapies, the good work will outcompete the bad. People will receive effective therapies and have them covered by their health insurance. But that is still in the future. In the meantime, we need to temper public hope. WORLD VIEWA personal take on events
